This study is looking at a medication called belimumab to see if it can help adults with systemic sclerosis associated interstitial lung disease (SSc-ILD). SSc-ILD is a condition where the immune system attacks the lungs and other parts of the body. Researchers want to know if belimumab is safe and effective when added to standard treatments. They will compare belimumab to a placebo (an inactive substance) to see how it affects lung function, skin thickening, and general symptoms like fatigue and quality of life. The study plans to enroll 300 participants. The current status of the study is unclear.

Study design

This study is comparing belimumab to a placebo in 300 participants. It is an interventional study, meaning participants will receive a specific treatment.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint measures changes in lung function at Week 52, suggesting follow-up for at least 52 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.